Published in Cancer Res on June 01, 2001
Nuclear functions of the HMG proteins. Biochim Biophys Acta (2009) 1.63
Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma. Mol Cell Biol (2003) 1.20
Identification of a New Pathway for Tumor Progression: MicroRNA-181b Up-Regulation and CBX7 Down-Regulation by HMGA1 Protein. Genes Cancer (2010) 1.13
Hmga1/Hmga2 double knock-out mice display a "superpygmy" phenotype. Biol Open (2014) 1.00
A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping. Endocr Relat Cancer (2007) 0.95
High mobility group A2 protein and its derivatives bind a specific region of the promoter of DNA repair gene ERCC1 and modulate its activity. Nucleic Acids Res (2003) 0.87
Functional relationship between high mobility group A1 (HMGA1) protein and insulin-like growth factor-binding protein 3 (IGFBP-3) in human chondrocytes. Arthritis Res Ther (2012) 0.78
A novel anti-proliferative role of HMGA2 in induction of apoptosis through caspase 2 in primary human fibroblast cells. Biosci Rep (2015) 0.77
Sex-specific molecular genetic response to UVB exposure in Xiphophorus maculatus skin. Comp Biochem Physiol C Toxicol Pharmacol (2015) 0.76
High mobility group A: a novel biomarker and therapeutic target in pancreatic adenocarcinoma. Surgeon (2009) 0.75
The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development. Curr Mol Med (2016) 0.75
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med (2001) 11.73
Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med (1999) 11.27
Ordered recruitment of chromatin modifying and general transcription factors to the IFN-beta promoter. Cell (2000) 6.32
Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J (1995) 5.59
MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer (2006) 4.11
Recruitment of CBP/p300 by the IFN beta enhanceosome is required for synergistic activation of transcription. Mol Cell (1998) 4.03
Mechanisms of transcriptional synergism between distinct virus-inducible enhancer elements. Cell (1993) 4.01
PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell (1990) 3.98
Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci U S A (1991) 3.95
Isolation of human glucose-6-phosphate dehydrogenase (G6PD) cDNA clones: primary structure of the protein and unusual 5' non-coding region. Nucleic Acids Res (1986) 3.86
Enhanceosomes. Curr Opin Genet Dev (2001) 3.30
Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene (2007) 3.29
Transcriptional activation by NF-kappaB requires multiple coactivators. Mol Cell Biol (1999) 3.11
Acetylation of HMG I(Y) by CBP turns off IFN beta expression by disrupting the enhanceosome. Mol Cell (1998) 3.09
Calorimetric determination of the enthalpy change for the alpha-helix to coil transition of an alanine peptide in water. Proc Natl Acad Sci U S A (1991) 2.84
Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science (1995) 2.83
Coordination of a transcriptional switch by HMGI(Y) acetylation. Science (2001) 2.69
Structural analysis of the X-linked gene encoding human glucose 6-phosphate dehydrogenase. EMBO J (1986) 2.64
A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature (1987) 2.60
The expression of a truncated HMGI-C gene induces gigantism associated with lipomatosis. Cancer Res (1999) 2.56
Structure of IRF-1 with bound DNA reveals determinants of interferon regulation. Nature (1998) 2.48
Bioactive IL-18 expression is up-regulated in Crohn's disease. J Immunol (1999) 2.38
Inhibition of HMGI-C protein synthesis suppresses retrovirally induced neoplastic transformation of rat thyroid cells. Mol Cell Biol (1995) 2.22
An HMG-like protein that can switch a transcriptional activator to a repressor. Nature (1994) 2.18
Nucleosome sliding via TBP DNA binding in vivo. Cell (2001) 2.16
Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto's thyroiditis. Laryngoscope (1997) 2.15
High level expression of the HMGI (Y) gene during embryonic development. Oncogene (1996) 2.13
Endothelial interferon regulatory factor 1 cooperates with NF-kappa B as a transcriptional activator of vascular cell adhesion molecule 1. Mol Cell Biol (1995) 2.12
Reversal of intrinsic DNA bends in the IFN beta gene enhancer by transcription factors and the architectural protein HMG I(Y). Cell (1995) 2.12
Role of the high mobility group A proteins in human lipomas. Carcinogenesis (2001) 2.08
RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. EMBO J (1994) 2.04
Nuclear integration of glucocorticoid receptor and nuclear factor-kappaB signaling by CREB-binding protein and steroid receptor coactivator-1. J Biol Chem (1998) 2.02
RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res (1998) 2.00
An ikaros-containing chromatin-remodeling complex in adult-type erythroid cells. Mol Cell Biol (2000) 1.97
High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene (1989) 1.94
Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood (1999) 1.89
A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene (2006) 1.89
Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. Oncogene (1994) 1.87
The spectrum of neurologic disease associated with anti-GM1 antibodies. Neurology (1990) 1.87
Isolation of a SIR-like gene, SIR-T8, that is overexpressed in thyroid carcinoma cell lines and tissues. Br J Cancer (2002) 1.87
Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocr Rev (2001) 1.85
Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. Oncogene (1993) 1.83
A striking similarity in the organization of the E-selectin and beta interferon gene promoters. Mol Cell Biol (1994) 1.75
Abnormal left ventricular intracavitary flow acceleration in patients undergoing aortic valve replacement for aortic stenosis. A marker for high postoperative morbidity and mortality. Circulation (1992) 1.72
Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia (2011) 1.70
Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation. Blood (1998) 1.68
The RET receptor: function in development and dysfunction in congenital malformation. Trends Genet (2001) 1.67
Cell-type-specific regulation of the human tumor necrosis factor alpha gene in B cells and T cells by NFATp and ATF-2/JUN. Mol Cell Biol (1996) 1.66
One- and two-step transformations of rat thyroid epithelial cells by retroviral oncogenes. Mol Cell Biol (1987) 1.66
The role of HMG I(Y) in the assembly and function of the IFN-beta enhanceosome. EMBO J (1999) 1.62
The expression of the high mobility group HMGI (Y) proteins correlates with the malignant phenotype of human thyroid neoplasias. Oncogene (1995) 1.61
Analysis of the HMGI nuclear proteins in mouse neoplastic cells induced by different procedures. Exp Cell Res (1989) 1.61
Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway. Proc Natl Acad Sci U S A (2001) 1.60
Graft-versus-myeloma effect: proof of principle. Blood (1996) 1.58
Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFkappaB p65 protein expression. Oncogene (1997) 1.57
Truncated and chimeric HMGI-C genes induce neoplastic transformation of NIH3T3 murine fibroblasts. Oncogene (1998) 1.52
Prostaglandin E2 inhibits proliferation and migration of HTR-8/SVneo cells, a human trophoblast-derived cell line. Placenta (2005) 1.52
Stimulus-specific assembly of enhancer complexes on the tumor necrosis factor alpha gene promoter. Mol Cell Biol (2000) 1.52
The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas. Oncogene (1990) 1.52
Neoplastic transformation of rat thyroid cells requires the junB and fra-1 gene induction which is dependent on the HMGI-C gene product. EMBO J (1997) 1.51
Distinct functional properties of IkappaB alpha and IkappaB beta. Mol Cell Biol (1997) 1.49